速递｜28周减重12.3%，辉瑞100亿美元月度GLP-1药物展现强劲减重效果

Core Viewpoint - Pfizer's PF'3944, a monthly injectable GLP-1 receptor agonist, shows promising weight loss results in its Phase IIb clinical trial, validating the company's $10 billion investment in the Metsera drug [4]. Group 1: Clinical Trial Results - In the Vesper-3 trial, approximately 250 overweight or obese adults without type 2 diabetes were randomly assigned to receive one of four dosing regimens of PF'3944 or a placebo [4]. - At week 28, the placebo-adjusted weight loss for the low and medium dose monthly maintenance regimens of PF'3944 was reported at 10% and 12.3%, respectively [4]. - Patients maintained stable weight loss after switching to monthly dosing, with no plateau observed at week 28, indicating potential for continued weight loss in the following weeks [4]. Group 2: Analyst Insights - BMO Capital Markets analysts expressed cautious optimism regarding the data, noting that a 12.3% weight loss at week 28 appears competitive, especially in combination studies with Pfizer's other projects [6]. - The monthly dosing data aligns with competitor performance, suggesting PF'3944 can provide competitive weight loss effects while avoiding the inconvenience of weekly injections [6]. - Pfizer plans to explore higher doses in its Phase III trials, with expectations that placebo-adjusted weight loss could reach around 16% based on high-dose predictions [6]. Group 3: Safety and Future Plans - Pfizer has not yet released complete safety data for week 28, but existing gastrointestinal adverse event data indicates that most side effects were mild to moderate, with few severe cases of nausea or vomiting [8]. - In the low and medium dose groups, 10 patients discontinued treatment due to adverse events, while no patients in the placebo group stopped treatment for this reason [8]. - Pfizer is initiating Phase III trials for PF'3944 with weekly dosing and plans to start an additional nine Phase III studies this year, focusing on both diabetic and non-diabetic patients, as well as evaluating monthly dosing regimens [8].